A phase II study of combination therapy with liposomal doxorubicin and carboplatin (CBDCA) in patients (pts) with previously untreated small cell lung cancer (SCLC)

7279 Background: SCLC remains an aggressive disease with a poor survival. Combinations with doxorubicin and CBDCA are the standard chemotherapy regimen for the treatment of SCLC. A wide variety of dose and schedules have been employed when managing these patients. Pegylated liposomal doxorubicin, has shown anti-tumour activity and reduced toxicity compared with standard doxorubicin. Methods: The objective of this phase II study is to determine efficacy and toxicity of Caelyx at a dose of 50mg/m2 in combination with CBDCA (AUC = 5), in patients with chemo-naive small cell lung cancer. A total of 6 - 8 cycles are repeated every 28 days. Results: Twenty-four patients have been entered to date. There are 17 males and 7 females. The median age is 63 years (range 42–73). The majority of patients (79%) presented with an ECOG PS of 0 - 1, despite the fact that more than 80% of patients presented with stage IV disease. A total of 108 cycles have been administered, with a median of 4 cycles (range 1–8). At this sta...